April 23, 2012
Experts to Discuss New Model to Assess Risks, Rewards of Regulating Medical Advancements
- RTI International will host a policy forum titled "Better Lives for Some, Shorter Lives for Others: Are New Drugs Worth the Risk?" on May 2
- Experts will discuss a new model for assessing the risks of new medical technologies and medications
- The event will take place at the National Press Club in Washington, D.C.
- Lisa Bistreich-Wolfe
- Kami Spangenberg
WASHINGTON, D.C. — A group of experts will gather at the National Press Club in Washington, D.C., May 2, to discuss a new model for assessing the risks of new medical technologies and medications.
The U.S. Food and Drug Administration is responsible for protecting patients from unsafe products, but tipping the balance too far in favor of safety can deny access to promising new medications and devices that could improve patient health or save lives.
The policy forum, titled "Better Lives for Some, Shorter Lives for Others: Are New Drugs Worth the Risk?", will bring together a group of thought leaders who represent public, private and academic communities to consider how patients' willingness to accept risks of new medications and medical technologies should be considered in regulatory decisions.
The event, to be held from 8:30 to 10 a.m., is being hosted by RTI International.
Speakers include Telba Irony, Ph.D., chief of the general surgical devices branch, Center for Devices and Radiological Health, U.S. Food and Drug Administration; F. Reed Johnson, Ph.D., distinguished fellow and principal economist at RTI International; Bennett Levitan, M.D., Ph.D., director, quantitative safety research, Department of Epidemiology, Janssen Research and Development; and Mitchell T. Wallin, M.D., M.P.H., clinical associate director, Multiple Sclerosis Center of Excellence, Baltimore Veterans Affairs (VA) Medical Center/University of Maryland.
Brett Hauber, senior economist and global head of health preference assessment, RTI Health Solutions, will moderate the program.
The event is the third forum of a seminar series that is exploring a variety of pressing public policy challenges facing our society.
For those who can't attend the event in person, follow #RTINEWDRUGS on Twitter.